Literature DB >> 1605604

Use of a predictor panel for development of a new disk for diffusion tests with cefoperazone-sulbactam.

P A Bradford1, C C Sanders.   

Abstract

The proper disk mass for diffusion susceptibility tests with cefoperazone-sulbactam was determined by using a predictor panel of clinical isolates that included staphylococci and gram-negative bacteria intrinsically susceptible, intrinsically resistant, and of various susceptibilities because of the production of different types and amounts of beta-lactamase. A primary panel of 24 isolates was used to screen various disk masses of cefoperazone and sulbactam in disk diffusion susceptibility tests. Regression analyses were performed for each combination by comparing MICs to zone diameters. Analysis of each component demonstrated that decreasing the disk mass of cefoperazone shifted the regression line to the left while decreasing the disk mass of sulbactam diminished the slope of the line. Ten candidate disks that adequately separated susceptible and resistant strains among the primary panel were identified, and these 10 disks, along with the previously proposed 75/30-micrograms disk, were then tested against an expanded panel of 265 isolates. Results indicated that a 30/20-micrograms cefoperazone-sulbactam disk provided the best separation between susceptible and resistant strains when interpretive criteria of less than or equal to 15 mm for resistance, 16 to 19 mm for moderate susceptibility, and greater than or equal to 20 mm for susceptibility were used. They also identified discrepancies between agar and broth microdilution MICs of sufficient size to warrant separate interpretive criteria for the two methods. Overall, the use of a predictor panel to develop interpretive criteria for susceptibility tests appeared to be a very useful approach, especially when antibiotics designed to be used against drug-resistant organisms are involved.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1605604      PMCID: PMC188447          DOI: 10.1128/AAC.36.2.394

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria.

Authors:  C N Baker; S A Stocker; D H Culver; C Thornsberry
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

2.  Interpretive criteria and quality control limits for ceftibuten disk susceptibility tests. Collaborative Antimicrobial Susceptibility Testing Group.

Authors:  A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

3.  Preliminary antimicrobial susceptibility interpretive criteria for cefetamet (Ro 15-8074) and cefteram (Ro 19-5247) disk tests.

Authors:  R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

4.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

5.  Type I beta-lactamases of gram-negative bacteria: interactions with beta-lactam antibiotics.

Authors:  C C Sanders; W E Sanders
Journal:  J Infect Dis       Date:  1986-11       Impact factor: 5.226

6.  Interpretive criteria and tentative quality control limits for apalcillin disk susceptibility tests.

Authors:  A L Barry; C Thornsberry; R N Jones; T L Gavan
Journal:  J Clin Microbiol       Date:  1984-06       Impact factor: 5.948

7.  In vitro activity and disk susceptibility of Timentin: current status.

Authors:  P C Fuchs; A L Barry; R N Jones
Journal:  Am J Med       Date:  1985-11-29       Impact factor: 4.965

8.  In vitro activities of ampicillin-sulbactam and cefoperazone-sulbactam against oxacillin-susceptible and oxacillin-resistant staphylococci.

Authors:  A L Barry; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

9.  Evaluation of the cefonicid disk test criteria, including disk quality control guidelines.

Authors:  A L Barry; R N Jones; C Thornsberry
Journal:  J Clin Microbiol       Date:  1983-02       Impact factor: 5.948

10.  Cefixime disk susceptibility test criteria.

Authors:  P C Fuchs; A L Barry; R N Jones
Journal:  J Clin Microbiol       Date:  1986-10       Impact factor: 5.948

View more
  9 in total

1.  Comparison of BD phoenix to vitek 2, microscan MICroSTREP, and Etest for antimicrobial susceptibility testing of Streptococcus pneumoniae.

Authors:  Scott A Mittman; Richard C Huard; Phyllis Della-Latta; Susan Whittier
Journal:  J Clin Microbiol       Date:  2009-09-09       Impact factor: 5.948

2.  Antimicrobial susceptibility of flavobacteria as determined by agar dilution and disk diffusion methods.

Authors:  J C Chang; P R Hsueh; J J Wu; S W Ho; W C Hsieh; K T Luh
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

3.  Use of a predictor panel to evaluate susceptibility testing methods for ampicillin-sulbactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

4.  Selection criteria for an antimicrobial susceptibility testing system.

Authors:  J H Jorgensen
Journal:  J Clin Microbiol       Date:  1993-11       Impact factor: 5.948

5.  Use of a predictor panel to evaluate susceptibility test methods proposed for piperacillin-tazobactam.

Authors:  P A Bradford; C C Sanders
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

6.  Catheter-associated urinary tract infections in intensive care units at a university hospital in Turkey.

Authors:  Derya Keten; Firdevs Aktas; Ozlem Guzel Tunccan; Murat Dizbay; Ayse Kalkanci; Gülsah Biter; Hamit Sirri Keten
Journal:  Bosn J Basic Med Sci       Date:  2014-11-14       Impact factor: 3.363

7.  Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates.

Authors:  L D Sutton; R N Jones
Journal:  J Clin Microbiol       Date:  1995-01       Impact factor: 5.948

8.  Cefepime : The Last Generation or the First Enhanced-Potency Broad Spectrum Cephalosporin?

Authors:  C C Sanders; E S Moland
Journal:  Clin Drug Investig       Date:  1995-12       Impact factor: 2.859

9.  Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489.

Authors:  Peter J Petersen; C Hal Jones; Aranapakam M Venkatesan; Tarek S Mansour; Steven J Projan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2008-11-10       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.